Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care

To develop and test a hybrid measure of muscle strength for juvenile dermatomyositis (JDM), which is based on the combination of the Manual Muscle Testing in 8 muscles (MMT‐8) and the Childhood Myositis Assessment Scale (CMAS) but is more comprehensive than the former and more feasible than the latter.

• Publication year

  2018

• Venue

  Arthritis care & research

• Publication date

  2018-08-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/acr.23491PMID 29245175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Psychometric Theory

  2020cited by this paper
• Chapter 26 – Juvenile Dermatomyositis

  2016cited by this paper
• Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis

  2012cited by this paper
• Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients

  2010cited by this paper
• The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study

  2010cited by this paper
• Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis.

  2009cited by this paper
• Developing outcome measures for paediatric rheumatic diseases.

  2009cited by this paper
• The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study.

  2008cited by this paper
• Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.

  2008cited by this paper
• Clinical assessment in juvenile dermatomyositis

  2006cited by this paper
• Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.

  2004cited by this paper
• International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.

  2004cited by this paper
• US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry.

  2003cited by this paper
• Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence.

  2003cited by this paper
• [Juvenile dermatomyositis].

  2002cited by this paper
• Clinimetric concepts in outcome assessment: the OMERACT filter.

  1999cited by this paper
• Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

  1999cited by this paper
• The OMERACT filter for Outcome Measures in Rheumatology.

  1998cited by this paper
• The incidence of juvenile dermatomyositis: results from a nation-wide study.

  1995cited by this paper
• Measurement of health status in children with juvenile rheumatoid arthritis.

  1994cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient Groups

  1994cited by this paper
• The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups.

  1994cited by this paper
• Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation.

  1991cited by this paper
• Polymyositis and dermatomyositis (first of two parts).

  1975cited by this paper
• Polymyositis and dermatomyositis (second of two parts).

  1975cited by this paper
• On correlation coefficients

  1966cited by this paper
• A primer of statistics for non-statisticians.

  1958cited by this paper
• Coefficient alpha and the internal structure of tests

  1951cited by this paper

• Toward a treat-to-target strategy in juvenile dermatomyositis: what are the suitable targets and optimal timing of their achievement?

  2025cites this paper
• Nailfold videocapillaroscopy in juvenile dermatomyositis: detailed correlations between microvascular abnormalities with clinical and laboratory parameters from an observational retrospective single-center study

  2025cites this paper
• Predictors of persistent active disease and the longitudinal development of organ damage, patient-reported outcomes and autoantibodies in long-term juvenile dermatomyositis

  2025cites this paper
• Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index

  2024cites this paper
• Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care

  2023cites this paper
• Outcome Scores in Pediatric Rheumatology

  2021cites this paper
• Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.

  2021cites this paper
• Long-term outcome in patients with juvenile dermatomyositis: A case series.

  2021cites this paper
• Development and Preliminary Validation of an Electromyography-Scoring Protocol for the Assessment and Grading of Muscle Involvement in Patients With Juvenile Idiopathic Inflammatory Myopathies.

  2021cites this paper
• Outcome Measures in Pediatric Rheumatic Disease.

  2021cites this paper
• Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.

  2021cites this paper
• Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis

  2020cites this paper
• [Juvenile dermatomyositis: A series of 22 cases].

  2020cites this paper
• The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

  2019cites this paper
• 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018.

  2019cites this paper
• Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.

  2019cites this paper
• A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy

  2019cites this paper
• Advances Toward Precision Medicine in Juvenile Dermatomyositis

  2019cites this paper
• Update on outcome assessment in myositis

  2018cites this paper
• Standardising measures in pediatric rheumatology: the experience of the international consensus dataset for juvenile dermatomyositis.

  2018cites this paper
• MRI assessment of the thigh musculature in dermatomyositis and healthy subjects using diffusion tensor imaging, intravoxel incoherent motion and dynamic DTI

  2018cites this paper
• Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis

  2018cites this paper